Insight

Ishwaria Subbiah: Refreshing to see excellence acknowledged

Ishwaria Subbiah and Vivek Subbiah

Nov 24, 2024, 18:00

Ishwaria Subbiah: Refreshing to see excellence acknowledged

Ishwaria Subbiah, Executive Director for Cancer Care Equity and Professional Wellness at Sarah Cannon Research Institute, shared on X:

“Don’t you love it when the good ones get recognized! Truly refreshing to see excellence acknowledged and celebrated! Bravo, Vivek Subbiah, on being among Clarivate’s Highly Cited Researchers!

He’s the guy who blocks the 30 minutes after his talks to ensure he gets to discuss with every person who comes up to him after!

Inspired by your impact-centered dedication to advancing oncology drug development! Excited for what’s ahead!”

Ishwaria Subbiah

More posts featuring Ishwaria Subbiah and Vivek Subbiah.

Ishwaria Subbiah is the Executive Director for Cancer Care Equity and Professional Wellness at Sarah Cannon Research Institute (SCRI). She is also the medical director of supportive care oncology, health equity and professional well being at The US Oncology Network.

Dr. Subbiah focuses on reducing cancer outcomes disparities and diversifying clinical trial participation within SCRI’s combined research network of over more than 1,300 physicians at over 250 locations in 24 states across the US. Dr. Subbiah is a globally recognized expert in geriatric oncology, symptom management, palliative care, and healthcare professional well-being.

She previously was an associate professor in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. She is the Chair for the ASCO Women in Oncology working group and the ASCO State of Cancer Care in America initiative.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.